32. Which of the following statements is true concerning a product that has a Risk Evaluation and Mitigation Strategy REMS program?
Answer: D
The product would not be on the market without a REMS program due to patient safety concerns.
A product with a Risk Evaluation and Mitigation Strategy (REMS) program is specifically designed to ensure that the benefits of the product outweigh its risks. Without a REMS program, the product would likely not receive regulatory approval for market entry due to potential safety concerns.
A) Compounding the product must be done according to instructions found in the REMS program
This option is incorrect because while REMS programs may include specific guidelines regarding the handling and dispensing of products, compounding is generally governed by other regulations and standards. REMS focuses on risk management rather than compounding procedures.
B) A product with a REMS program is more likely to be involved in misuse or diversion
This statement is misleading. While products with REMS programs may be associated with higher risks of misuse or diversion, the purpose of the REMS is to mitigate those risks. Therefore, the presence of a REMS program is a proactive approach to managing potential misuse rather than an indication that the product is inherently more likely to be misused.
C) Whether to adhere to the product's REMS program guidelines is determined by pharmacist discretion
This option is incorrect as adherence to REMS program guidelines is mandatory and not left to pharmacist discretion. Pharmacists are required to follow the REMS protocols to ensure patient safety and compliance with regulatory standards.
D) The product would not be on the market without a REMS program due to patient safety concerns
This statement is accurate. Regulatory authorities require REMS programs for certain products to ensure that their risks are managed effectively, which is a critical factor for allowing these products to be sold in the market. The presence of a REMS program indicates that the product has undergone a thorough safety evaluation.
Conclusion
Option D is the correct choice as it accurately reflects the necessity of a REMS program for certain products, ensuring that they can be marketed safely. Other options either misinterpret the role of REMS programs or incorrectly suggest that adherence is optional, highlighting their inadequacy in addressing the core concept of risk management in pharmaceuticals.